Heart Failure, Systolic
Conditions
Keywords
PRMT5, Heart failure, cardiac function and cardiac structure
Brief summary
Pathological cardiac hypertrophy is characterized by abnormal cardiomyocyte metabolism, reduced myocardial contractility, and dysregulated synthesis of myocardial contractile proteins. This pathological process leads to progressive impairment of cardiac function and ultimately progresses to heart failure. Previous studies have demonstrated that PRMT5 exerts a significant inhibitory effect on heart failure, yet its clinical significance in the context of heart failure remains undefined. In this study, we hypothesized that serum PRMT5 may serve as a biomarker to predict cardiac structural parameters and functional indices. Therefore, we aim to analyse the correlation between serum PRMT5 levels and the following parameters-LVPWs, LVPWd, LVIDs, LVIDd, IVSTs, IVSTd, EF, FS, LVMi and RWT on the first day when participants are enrolled in this study.
Detailed description
The aim of this study is to collect blood samples from both healthy controls and heart failure patients and to clarify the correlation between serum PRMT5 levels on the first day of enrollment and cardiac ultrasound indicators. Serum PRMT5 levels are measured by means of enzyme-linked immunosorbent assay (ELISA). Left ventricular posterior wall thickness at end-systole (LVPWs), Left ventricular posterior wall thickness at end-diastole (LVPWd), left ventricular internal diameter at end-systole (LVIDs), left ventricular internal diameter at end-diastole (LVIDd), interventricular septum at end-systole (IVSTs) and interventricular septal septum at end-diastole (IVSTd) are measured on the first day of enrollment via echocardiography. Ejection fraction (EF), fractional shortening (FS), left ventricular mass index (LVMi), and relative wall thickness (RWT) are subsequently calculated based on LVIDd, LVPWd, and IVSTd values. Finally, the correlations between serum PRMT5 levels and the following indicators are analyzed: LVPWs, LVPWd, LVIDs, LVIDd, IVSTs, IVSTd, EF, FS, LVMi and RWT.
Interventions
None listed
Sponsors
The University of Hong Kong-Shenzhen Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Healthy group: Aged ≥18 years (both sexes), systolic blood pressure (SBP) ≤120 mmHg and diastolic blood pressure (DBP) ≤80 mmHg, no history of cardiovascular diseases, ejection fraction (EF) ≥50%. Heart failure group: Aged ≥18 years (both sexes), EF ≤50%.
Exclusion criteria
*
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Serum PRMT5 level at baseline | Baseline (day of informed consent agreement and blood sampling) | Serum PRMT5 level is analysed at the day of informed consent agreement and blood sampling |
| LVIDs level at baseline | Baseline | Left ventricular internal diameter at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination |
| LVIDd level at baseline | Baseline | Left ventricular internal diameter at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination |
| LVPWs level at baseline | Baseline | left ventricular posterior wall at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination |
| LVPWd level at baseline | Baseline | left ventricular posterior wall at diastole state is measured at the day of informed consent agreement and cardiac ultrasound examination |
| IVSTs at baseline | Baseline | Interventricular septum at systolic state is measured at the day of informed consent agreement and cardiac ultrasound examination |
| IVSTd at baseline | Baseline | Interventricular septum at diastolic state is measured at the day of informed consent agreement and cardiac ultrasound examination |
| EF at baseline | Baseline | Ejection fraction is calculated according to the formula below: 1. EF=(LVEDV-LVESV)/LVEDV\*100%; 2. LVEDV=(7.0\*LVIDd\^3)/(2.4+LVIDd) 3. LVESV=(7.0\*LVIDs\^3)/(2.4+LVIDs) |
| FS at baseline | Baseline | Fractional shortening is calculated based on the formula below: FS=(LVIDd-LVIDs)/LVIDd\*100% |
| LVMi at baseline | Baseline | Left ventricular mass index is calculated according to the formula below: 1. LVMi(g/m\^2)=LVM/BSA; 2. LVM(g)=LVM=0.8×1.04×\[(LVIDd+IVSd+LVPWd)\^3-LVIDd\^3\]+0.6; 3. BSA(m\^2)=0.007184×W\^0.425×H\^0.725 (W: Weight, kg; H: Height, cm) |
| RWT at baseline | Baseline | Relative wall thickness is calculated according to the formula below: RWT=2\*(IVSd+LVPWd)/LVIDd |
Countries
China
Outcome results
None listed